艾米克斯生物制药
IMMX
7.98
-0.70
-8.06%
艾米克斯生物制药
US · IMMX
#3426 按市值排名
上市于 2021
7.98
-0.70
-8.06%
实时 - 追踪5344个代码 - 心跳于284秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期(2026/Q3)披露持股的机构数量增加了2家。
- 机构持股总比例下降了12.0个百分点。
机构持股
- 机构持股比例
- 74.77% -11.95pp
- 机构数量
- 136 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份,同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund42.39%
Hedge Fund17.60%
VC/PE Fund8.53%
Individual/Insider8.20%
Private Company5.22%
Public Company0.84%
Insurance Company0.11%
Other17.04%
主要股东 截至 2026-06-30
Janus Henderson Group plc
11.80% · 9.78M 股
Saturn V Capital Management LP
5.62% · 4.66M 股
Veritas Liberabit Vos, LLC
4.72% · 3.92M 股
Eventide Asset Management, LLC
4.69% · 3.89M 股
Yekaterina Chudnovsky
3.91% · 3.24M 股
State Street Global Advisors
3.61% · 3.00M 股
BlackRock
3.61% · 2.99M 股
Vanguard Capital Management, LLC
3.51% · 2.91M 股
Deep Track Capital, LP
3.35% · 2.78M 股
Opaleye Management Inc.
2.83% · 2.35M 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 47次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Yekaterina Chudnovsky | Director | 3.91% |
| Ilya Rachman | Chairperson & CEO | 1.38% |
| Jason Hsu | Director | 1.14% |
| Patricia Gallup | -- | 0.60% |
| Nancy Chang | Director | 0.51% |
| Gabriel Morris | Chief Financial Officer | 0.35% |
| Helen Adams | Independent Director | 0.21% |
| Magda Marquet | Independent Director | 0.06% |
| Jane Buchan | Independent Director | 0.03% |
| Carey Ng | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-05-21 | Nancy Chang | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Nancy Chang | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Jane Buchan | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Jane Buchan | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Jason Hsu | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Jason Hsu | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Magda Marquet | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Magda Marquet | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Helen Adams | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Helen Adams | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Carey Ng | Independent Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Carey Ng | Independent Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2026-05-21 | Ilya Rachman | Chairperson & CEO | Other Derivative Acquisition | +500,000 | $8.78 |
| 2026-05-21 | Gabriel Morris | Chief Financial Officer | Other Derivative Acquisition | +500,000 | $8.78 |
| 2026-05-21 | Yekaterina Chudnovsky | Director | Other Acquisition | +6,250 | -- |
| 2026-05-21 | Yekaterina Chudnovsky | Director | Other Derivative Acquisition | +12,500 | $8.78 |
| 2025-12-09 | Ilya Rachman | Chairperson & CEO | Open Market Acquisition | +746 | $6.67 |
| 2025-12-09 | Gabriel Morris | Chief Financial Officer | Open Market Acquisition | +770 | $6.58 |
| 2025-12-07 | Alwaysraise LLC | -- | Derivative Exercise and Retained | +156,000 | $0.80 |
| 2025-11-20 | Nancy Chang | Director | Other Derivative Acquisition | +39,643 | $4.33 |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
艾米克斯生物制药 讨论区 0 条评论